How would you approach moderate neutropenia (ANC < 1000) in a solid organ transplant recipient?

There are limited data addressing the safety and efficacy of G-CSF in the solid-organ post-transplantation setting. Most case series report no increase in graft rejection with G-CSF treatment, although this question is not rigorously answered. Most cases of neutropenia in the post solid-organ transp...

That is a very difficult question that depends on a lot of variables related to the transplant: which meds, degree of immunosuppression, risks of rejection, and others. It is best discussed with the patient's own transplant physicians.